ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Comment on: "GLM7 - A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity".
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply to the Comments on "GLM7-A Novel Composite Glycolipid Index Derived from Routine Health Indicators for Enhanced Diagnosis and Prediction of Multimorbidity".Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Association of the GLM7 composite metabolic index with gestational diabetes mellitus in early pregnancy: a secondary analysis of a Korean prospective pregnancy cohort.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent study by Wang et al. introduces GLM7, a novel composite index integrating routine health indicators to enhance the diagnosis and prediction of multimorbidity. The study provides compelling evidence for the utility of cost-effective biomarkers in large-scale health screening. In this comment, we engage in a constructive discussion regarding the methodological interpretation of the index. Specifically, we explore the implications of incorporating diagnostic criteria (such as fasting blood glucose) into predictive models for diabetes, the mathematical nuance required when comparing Odds Ratios (ORs) between logarithmic indices and linear variables, and the structural contribution of age within the composite formula. We believe that addressing these aspects could further solidify the clinical applicability and interpretability of GLM7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.